TREM2 agonism promotes microglial phagocytosis and metabolic reprogramming, shifting microglia from disease-associated (DAM) to homeostatic state. AL002c (Alector) already in Phase II trials, making this the most translation-ready hypothesis.
Auto-built from this analysis's top knowledge-graph edges.
graph TD
TREM2["TREM2"] -->|regulates| microglial_metabolic_repr["microglial metabolic reprogramming"]
TREM2_deficiency["TREM2 deficiency"] -->|causes| impaired_amyloid_plaque_e["impaired amyloid plaque enclosure"]
TREM2_agonism["TREM2 agonism"] -->|protective against| amyloid_associated_neurot["amyloid-associated neurotoxicity"]
TREM2_agonism_1["TREM2 agonism"] -->|prevents| amyloid_associated_neurot_2["amyloid-associated neurotoxicity"]
TREM2_deficient_microglia["TREM2-deficient microglia"] -.->|inhibits| amyloid_plaque_enclosure["amyloid plaque enclosure"]
TREM2_expression["TREM2 expression"] -->|biomarker for| amyloid_burden["amyloid burden"]
style TREM2 fill:#4fc3f7,stroke:#333,color:#000
style microglial_metabolic_repr fill:#4fc3f7,stroke:#333,color:#000
style TREM2_deficiency fill:#4fc3f7,stroke:#333,color:#000
style impaired_amyloid_plaque_e fill:#4fc3f7,stroke:#333,color:#000
style TREM2_agonism fill:#4fc3f7,stroke:#333,color:#000
style amyloid_associated_neurot fill:#4fc3f7,stroke:#333,color:#000
style TREM2_agonism_1 fill:#4fc3f7,stroke:#333,color:#000
style amyloid_associated_neurot_2 fill:#4fc3f7,stroke:#333,color:#000
style TREM2_deficient_microglia fill:#4fc3f7,stroke:#333,color:#000
style amyloid_plaque_enclosure fill:#4fc3f7,stroke:#333,color:#000
style TREM2_expression fill:#4fc3f7,stroke:#333,color:#000
style amyloid_burden fill:#4fc3f7,stroke:#333,color:#000No linked papers recorded for this hypothesis yet.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF AL002c is administered at the Phase II dose (10 mg/kg IV every 4 weeks for 48 weeks) to early-stage Alzheimer's disease subjects with elevated amyloid burden (Centiloid > 50), THEN amyloid-beta pla | Mean reduction in cerebral amyloid-beta PET SUVR of ≥ 0.15 from baseline to week 48 in the AL002c-treated arm versus placebo | — no observation — | pending | 0.35 |
| IF AL002c agonism successfully shifts microglia toward a homeostatic state, THEN CSF concentration of soluble TREM2 (sTREM2) will increase by ≥ 30% and CSF levels of disease-associated microglia marke | ≥ 30% increase in CSF sTREM2 and ≥ 25% decrease in CSF SPP1/opsonin-related DAM markers in the AL002c arm versus placebo at 24 weeks | — no observation — | pending | 0.40 |